The Cecelia Health team is committed to the mission of improving patients’ health as well as reducing the cost of care. A recent independent study, conducted by the Jaeb Center for Health Research with funding from the Helmsley Charitable Trust, demonstrated successful remote continuous glucose monitor (CGM) initiation and sustained CGM use to improve diabetes outcomes and quality of life for people living with diabetes via the support of Certified Diabetes and Education Specialists (CDCES) from Cecelia Health.ĭana Callow, Managing General Partner at Boston Millennia Partners said, “Cecelia Health fits our belief that therapeutic adherence is a combination service and product business.
The company’s scalable telemedicine and digital health model is designed to quickly serve a broad population of patients at a low cost. With over one million remote patient interactions, Cecelia Health has been a pioneer in delivering telehealth and chronic disease management solutions. Our firm is excited to lead this round with Rittenhouse Ventures and partner with the team at Cecelia Health as they continue to solve for fundamental access, affordability, new technology adoption, patient experience and other challenges people with diabetes face on a daily basis.” “I have seen this firsthand, as my family is a user of a Cecelia Health certified diabetes educator. "The support provided by Cecelia Health to people with diabetes is truly life changing,” said Eric Edidin, President of Endo Investors. Cecelia Health has most recently demonstrated the long-term value of an integrated and specialized virtual care model and ability to fill critical telehealth gaps for patients via the telemedicine assistance it is providing to top diabetes clinics during the COVID-19 pandemic. I’m also excited to have Saul Richter from Rittenhouse, and Eric Edidin from Endo Investors join the Board as part of this funding round.”Ĭecelia Health has emerged as a leader in using expert clinicians that leverage a technology-enabled digital health platform. “The new investment capital from Rittenhouse, Endo, Boston Millennia, SustainVC and G100, and the executive access they will provide to new health plan, pharmaceutical and medical device companies and self-insured employers will enable us to accelerate our mission to transform lives at scale. “The market opportunity and demand for Cecelia Health’s telehealth solutions has grown exponentially since the onset of COVID-19 due to our demonstrated track record for significantly improving the health outcomes and quality of life for people living with diabetes and other chronic conditions,” said David Weingard, Founder and CEO of Cecelia Health. The funding will enable the company to accelerate and further scale the adoption of the company's technology enabled coaching and telemedicine solutions and expand Cecelia Health’s digital health capabilities. The investment was co-led by Rittenhouse Ventures and Endo Investors, and includes investments from Boston Millennia Partners, SustainVC, G100 Capital, and others.
Cecelia Health, a leading technology-enabled diabetes and other chronic disease management company, announced today it has completed a $13 million Series B funding round.